Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE: MTEC) (Frankfurt: 3CM) (OTC:CANVF), a leading digital cannabis education and analytics company, is pleased to appoint Brad Poulos to its Educational Advisory Board. Mr. Poulos is currently on faculty and teaching the Business of Cannabis at the Ted Rogers School of Management at Toronto’s Ryerson University, and an in-demand public speaker on the topics of business and the cannabis industry. Mr. Poulos will provide independent oversight and guidance for content on the Cannvas.Me educational platform.

“Brad is an exceptional educator and successful entrepreneur, and we will lean on his expertise and acumen in business, cannabis and higher education circles to elevate the quality and substance of our content on Cannvas.Me,” said Daniel Davidzon, Director of Strategy and Education, Cannvas MedTech. “A seasoned professional and sought-after industry expert across several sectors, Brad’s experience in building and delivering the Business of Cannabis course at Ryerson University will be invaluable as we expand the educational offerings on Cannvas.Me.”


At The Ted Rogers School of Management, in collaboration with Ryerson University’s Chang School of Continuing Education, Mr. Poulos, a 10-year veteran lecturer in entrepreneurship strategy, launched an introductory course called “The Business of Cannabis” after having spent several years researching the industry. Though Ryerson is currently the only university to offer a business course on cannabis in Ontario, Durham College offers a specialization certificate on the cannabis industry taught by another member of the Cannvas Education Advisory Board, Ms. Angela Smith, PhD.

With over 30 years experience across a range of industries including education, cannabis, telecommunications and software, Mr. Poulos has focused on running and advising companies with issues related to growth and business development, optimization and strategy. He currently sits on the Boards of two other companies: Budtender, an industry-leading cannabis customer experience platform, and AXSource, a global regulatory & quality consulting firm. A former profit 100 CEO and public company chair, his unique insights and analysis are in constant demand for media and speaking opportunities.

Members of the Cannvas Medical, Educational and Cannabis Sciences Advisory Board offer independent oversight and guidance to the Cannvas.Me digital cannabis education platform, helping craft and curate original content for cannabis-curious Canadians looking to learn more about all aspects of the plant.

About Cannvas
Cannvas is a leading digital cannabis education and analytics company delivering accessible and evidence-based education while harnessing the power of data to paint a clearer picture of cannabis consumption across Canada.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

Click here to connect with Cannvas MedTech (CSE:MTEC) for an Investor Presentation.

Source: www.newswire.ca

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less